Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Northwest Biotherapeutics (DE:NBYB)
BERLIN:NBYB
Northwest Biotherapeutics (NBYB) Stock Price & Analysis
0 Followers
NBYB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.39 - €1.06
Previous Close€0.47
Volume0.00
Average Volume (3M)3.71K
Market Cap
€571.52M
Enterprise Value€600.40M
Total Cash (Recent Filing)$2.13M
Total Debt (Recent Filing)$32.79M
Price to Earnings (P/E)N/A
Beta-1.25
Next Earnings
May 16, 2018EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume3,714
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue551.84
Enterprise Value/Gross Profit310.77
Enterprise Value/Ebitda-10.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Northwest Biotherapeutics News
PremiumCompany Announcements
Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
PremiumCompany Announcements
Northwest Biotherapeutics Board Veteran Jasinowski Retires
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
NBYB FAQ
What was Northwest Biotherapeutics’s price range in the past 12 months?
Northwest Biotherapeutics lowest stock price was €0.39 and its highest was €1.06 in the past 12 months.
What is Northwest Biotherapeutics’s market cap?
Currently, no data Available
When is Northwest Biotherapeutics’s upcoming earnings report date?
Northwest Biotherapeutics’s upcoming earnings report date is May 16, 2018 which is 2180 days ago.
How were Northwest Biotherapeutics’s earnings last quarter?
Currently, no data Available
Is Northwest Biotherapeutics overvalued?
According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued.
Does Northwest Biotherapeutics pay dividends?
Northwest Biotherapeutics does not currently pay dividends.
What is Northwest Biotherapeutics’s EPS estimate?
Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Northwest Biotherapeutics have?
Currently, no data Available
What happened to Northwest Biotherapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Northwest Biotherapeutics?
Among the largest hedge funds holding Northwest Biotherapeutics’s share is Fisher Asset Management LLC. It holds Northwest Biotherapeutics’s shares valued at N/A.
---
Northwest Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.01%
Trailing 12-Months
Company Description
Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
---
Technical Analysis
Fate Therapeutics
―
Corvus Pharmaceuticals
―
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
Northwest Biotherapeutics
―
---